Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction

被引:69
作者
Ganz, DA
Kuntz, KM
Jacobson, GA
Avorn, J
机构
[1] Harvard Univ, Sch Publ Hlth, Ctr Risk Anal, Boston, MA 02115 USA
[2] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
关键词
D O I
10.7326/0003-4819-132-10-200005160-00003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy has proven efficacy in reducing the rate of coronary and cerebrovascular events in patients 75 years of age or younger with a history of myocardial infarction. However, in patients older than 75 years of age, the efficacy and potential cost-effectiveness of statins are unknown. Objective: To estimate the incremental cost-effectiveness of statin therapy compared with usual care in patients 75 to 84 years of age with previous myocardial infarction. Design: Cost-effectiveness analysis. Data Sources: Published data from cohort studies. Target Population: Patients 75 to 84 years of age with a history of myocardial infarction. Time Horizon: Lifetime. Perspective: Societal. Intervention: Statin therapy. Outcome Measures: Life expectancy, quality-adjusted life expectancy, and incremental cost-effectiveness. Results of Base-Case Analysis: The incremental cost-effectiveness of statin therapy compared with usual care in patients 75 to 84 years of age with previous myocardial infarction was $18 800 per quality-adjusted life-year (QALY). Results of Sensitivity Analysis: On the basis of a probabilistic sensitivity analysis, there is a 75% chance that statin therapy costs less than $39 800 per QALY compared with usual care. If the cost of statin therapy and efficacy of statin therapy at reducing myocardial infarction were set to their most favorable values, statin therapy cost $5400 per QALY; if cost and efficacy were set to their least favorable values, statin therapy cost $97 800 per QALY. Conclusions: The cost-effectiveness ratios of statin therapy in older patients with previous myocardial infarction are reasonable under a wide variety of assumptions about drug efficacy, drug cost, and rates of cardiac and cerebrovascular events. Pending results of randomized, controlled trials of secondary prevention in patients in this age group, statin therapy seems to be as cost-effective as many routinely accepted medical interventions in this setting.
引用
收藏
页码:780 / 787
页数:8
相关论文
共 40 条
  • [1] [Anonymous], DRG HDB COMP CLIN FI
  • [2] PROGNOSTIC-SIGNIFICANCE OF NONFATAL MYOCARDIAL REINFARCTION
    BENHORIN, J
    MOSS, AJ
    OAKES, D
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1990, 15 (02) : 253 - 258
  • [3] The west of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin
    Caro, J
    Klittich, W
    McGuire, A
    Ford, J
    Norrie, J
    Pettitt, D
    McMurray, J
    Shepherd, J
    [J]. BRITISH MEDICAL JOURNAL, 1997, 315 (7122) : 1577 - 1582
  • [4] Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT)
    Davis, BR
    Cutler, JA
    Gordon, DJ
    Furberg, CD
    Wright, JT
    Cushman, WC
    Grimm, RH
    LaRosa, J
    Whelton, PK
    Perry, HM
    Alderman, MH
    Ford, CE
    Oparil, S
    Francis, C
    Proschan, M
    Pressel, S
    Black, HR
    Hawkins, CM
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 1996, 9 (04) : 342 - 360
  • [5] LONG-TERM SURVIVAL AFTER 1ST-EVER STROKE - THE OXFORDSHIRE COMMUNITY STROKE PROJECT
    DENNIS, MS
    BURN, JPS
    SANDERCOCK, PAG
    BAMFORD, JM
    WADE, DT
    WARLOW, CP
    [J]. STROKE, 1993, 24 (06) : 796 - 800
  • [6] Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205
  • [7] Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS
    Downs, JR
    Clearfield, M
    Weis, S
    Whitney, E
    Shapiro, DR
    Beere, PA
    Langendorfer, A
    Stein, EA
    Kruyer, W
    Gotto, AM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20): : 1615 - 1622
  • [8] The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life
    Gage, BF
    Cardinalli, AB
    Owens, DK
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (16) : 1829 - 1836
  • [9] The efficacy and safety of pravastatin in patients aged 60 to 85 years with low-density lipoprotein cholesterol >160 mg/dl
    Glasser, SP
    DiBianco, R
    Effron, BA
    Faas, F
    Germino, FW
    Shane, LE
    Unger, AH
    Staggers, JE
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1996, 77 (01) : 83 - 85
  • [10] GOLD MR, 1996, COST EFFECTIVENESS H, P198